Zoetis (ZTS) Surpasses Market Returns: Some Facts Worth Knowing

Zoetis (ZTS) shares rose 1.5% to $168.82, outperforming the S&P 500's 0.38% gain, with anticipation building for the upcoming earnings release where EPS is expected to rise 3.21% year-over-year to $1.61 and revenue to increase 1.67% to $2.4 billion. Full-year estimates project a 5.74% EPS increase to $6.26 and a 2.53% revenue increase to $9.49 billion. The stock currently holds a Zacks Rank of #3 (Hold) and trades at a premium with a Forward P/E of 26.59 compared to the industry average of 16.43.

Analysis

Zoetis (ZTS) has demonstrated notable recent strength, with its stock closing at $168.82 reflecting a 1.5% increase in the last trading session and a significant 7.37% gain over the past month, thereby outperforming the S&P 500, the Dow, the Nasdaq, and the broader Medical sector. Market participants are keenly awaiting the company's upcoming earnings release, where Zoetis is anticipated to report earnings per share (EPS) of $1.61, a 3.21% year-over-year increase, and revenue of $2.4 billion, up 1.67% from the prior year's quarter. For the full year, Zacks Consensus Estimates project an EPS of $6.26, representing a 5.74% year-over-year growth, and revenue of $9.49 billion, a 2.53% increase. While recent positive analyst estimate revisions, including a 0.04% uptick in the Zacks Consensus EPS estimate over the last 30 days, signal some optimism regarding the business outlook, Zoetis currently holds a Zacks Rank of #3 (Hold). From a valuation perspective, ZTS trades at a forward P/E ratio of 26.59, a premium compared to its industry's average of 16.43, and possesses a PEG ratio of 2.76, which is also above the Medical - Drugs industry average of 1.74. The Medical - Drugs industry itself is positioned favorably, ranking in the top 29% of over 250 industries tracked by Zacks.

Key Decisions for Investors

• Investors should closely monitor Zoetis's upcoming earnings report to ascertain if the company meets or surpasses the expected EPS of $1.61 and revenue of $2.4 billion, as these results will be pivotal for near-term stock momentum.
• Given the stock's premium valuation, evidenced by a Forward P/E of 26.59 and a PEG ratio of 2.76, it is prudent to evaluate whether the projected full-year earnings growth of 5.74% and revenue growth of 2.53% adequately justify these multiples before committing new capital.
• The current Zacks Rank of #3 (Hold), coupled with the modest 0.04% increase in consensus EPS estimates, suggests a neutral short-term outlook; therefore, consider awaiting more substantial positive catalysts or a more attractive valuation entry point before adopting a strong bullish stance.